哌啶-4-甲酰氯盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 哌啶-4-甲酰氯盐酸盐
• 英文名称: 4-chloro-carbonyl piperidine hydrochloride
• 英文别名: isonipecotic acid chloride hydrochloride；hydron;piperidine-4-carbonyl chloride;chloride
• 化学式: C₆H₁₀ClNO*ClH
• 分子量: 184.065
• InChiKey: SYNYPRPWBDWELP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.17
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  哌啶-4-甲酰氯盐酸盐 、 替拉替尼 在 sodium dithionite 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.5h， 以60%的产率得到(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-14-(allylamino)-12,15,13-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-2-aza-1(1,3)-benzenacycloheptadecaphane-4,6,10-trien-9-yl carbamate piperidine-4-carboxylate hydrochloride
  参考文献：
  名称：

  [EN] METHODS OF TREATING LIPOSARCOMA
  [FR] PROCÉDÉS DE TRAITEMENT DU LIPOSARCOME

  摘要：

  本文提供了一种治疗脂肪肉瘤的方法，该方法包括向受试者施用治疗有效量的Hsp90抑制剂。

  公开号：

  WO2010135426A1

文献信息

• [EN] ANALOGS OF BENZOQUINONE-CONTAINING ANSAMYCINS FOR THE TREATMENT OF CANCER<br/>[FR] ANALOGUES D'ANSAMYCINES CONTENANT DE LA BENZOQUINONE POUR LE TRAITEMENT DU CANCER
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2005063714A1

  公开（公告）日：2005-07-14

  The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer ( formula (I) and (IV). The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting (17)-­ammonium hydroquinone ansamycin analog.

  本发明提供了含苯醌的ansamycins的类似物及其用于治疗和调节与过度增殖相关的疾病，如癌症（公式（I）和（IV））。本发明提供了含苯醌的ansamycins的类似物，其中苯醌被还原为氢醌，并通过与适当酸反应而被困，最好是增加所得（17）-氨基氢醌ansamycin类似物的溶解性和空气稳定性的酸。
• Neuroleptic-4-(naphthylmethyl)piperidine derivatives
  申请人：Richardson-Merrell Inc.

  公开号：US04246268A1

  公开（公告）日：1981-01-20

  Novel compounds of the formula ##STR1## wherein n is an integer of from 2 to 5, R is hydrogen, alkyl, alkoxy, halogen or trifluoromethyl, R.sub.1 is hydrogen, alkyl, alkoxy or halogen, X is carbonyl, hydroxymethylene or methylene, and Z is carbonyl or hydroxymethylene and their pharmaceutically acceptable acid addition salts are useful as antipsychotic agents having a low potential for extrapyramidal side effects. The novel compounds are prepared from novel intermediates of formula ##STR2## or their salts wherein R and X have the meanings defined above.

  化合物的新型化合物的公式为##STR1##其中n是从2到5的整数，R是氢，烷基，烷氧基，卤素或三氟甲基，R.sub.1是氢，烷基，烷氧基或卤素，X是羰基，羟甲基或亚甲基，Z是羰基或羟甲基及其药用酸盐是有用的抗精神病药物，具有低的外周神经副作用潜力。这些新型化合物是从新型中间体的公式##STR2##或其盐制备而成，其中R和X具有上述定义的含义。
• N-aralkyl piperidine derivatives useful as antithrombolytic agents
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05093341A1

  公开（公告）日：1992-03-03

  The present invention is directed to a new class of compounds useful as antiarrhythmics, analgesics and serotonin 5HT.sub.2 antagonists, which compounds have the following formula: ##STR1## wherein; Y is represented by H, CO(CH.sub.2).sub.n CH.sub.3 in which n is an integer from 0-3, or SO.sub.2 (CH.sub.2).sub.n CH.sub.3 in which n is an integer from 0--3; X is represented CO, CHOH, or C.dbd.N--O--A, wherein A is represented by hydrogen or a C.sub.1-4 alkyl; R is either selected from the group consisting of halogens, lower alkyl groups, lower alkoxy groups, and hydrogen or R is a divalent substituent and is represented by a 3,4-methylenedioxy or a 3,4-ethylenedioxy substituent; m is an integer from 1-5; and the pharmaceutically acceptable acid addition salts thereof.

  本发明涉及一类新的化合物，可用作抗心律失常药、镇痛药和5-羟色胺受体拮抗剂，这些化合物具有以下结构式：##STR1## 其中；Y由H、CO(CH.sub.2).sub.n CH.sub.3（其中n为0-3的整数）或SO.sub.2 (CH.sub.2).sub.n CH.sub.3（其中n为0-3的整数）表示；X由CO、CHOH或C.dbd.N--O--A（其中A表示氢或C.sub.1-4烷基）表示；R从卤素、低烷基基团、低烷氧基团和氢中选择，或R是一种二价取代基，表示为3,4-亚甲二氧基或3,4-乙烯二氧基取代基；m为1-5的整数；以及其药用可接受的酸盐。
• Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
  申请人：Rao Srirama P.

  公开号：US20060069124A1

  公开（公告）日：2006-03-30

  Methods of modulating eosinophil migration, chemotaxis or generation, in vitro, ex vivo, and in vivo are provided. Methods include contacting eosinophils with an amount of 5-HT2A receptor agonist or antagonist sufficient to modulate eosinophil migration, chemotaxis or generation.

  提供了调节嗜酸性粒细胞在体外、体内和体内迁移、趋化或生成的方法。方法包括将嗜酸性粒细胞与足以调节嗜酸性粒细胞迁移、趋化或生成的5-HT2A受体激动剂或拮抗剂进行接触。
• Antithrombotic compounds
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05292752A1

  公开（公告）日：1994-03-08

  The present invention is directed to a new class of piperidinyl medicinal agents which are useful as antithrombotic agents and as serotonin 5HT.sub.2 antagonists.

  本发明涉及一种新型的哌啶类药物，可用作抗血栓药物和血清素5HT.sub.2拮抗剂。